Hostname: page-component-848d4c4894-pjpqr Total loading time: 0 Render date: 2024-06-14T16:10:08.178Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevalence of insulin resistance and diabetes mellitus type II in bipolar disorders

Published online by Cambridge University Press:  23 March 2020

L. Steardo ,
A. Tortorella ,
M. Fabrazzo ,
G. Del Buono ,
S. Ambrosio  and
P. Monteleone
L. Steardo*
Affiliation:
University of Naples Sun, Department of Psychiatry, Naples, Italy
A. Tortorella
Affiliation:
University of Naples Sun, Department of Psychiatry, Naples, Italy
M. Fabrazzo
Affiliation:
University of Naples Sun, Department of Psychiatry, Naples, Italy
G. Del Buono
Affiliation:
University of Salerno, Neurosciences Section-Department of Medicine and Surgery, Salerno, Italy
S. Ambrosio
Affiliation:
University of Salerno, Neurosciences Section-Department of Medicine and Surgery, Salerno, Italy
P. Monteleone
Affiliation:
University of Salerno, Neurosciences Section-Department of Medicine and Surgery, Salerno, Italy
*
* Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Bipolar disorder (BD) is associated with high morbidity and mortality. Patients are symptomatic almost half of their lives and experience significant disability. One subtype of BD is associated with a more chronic course, refractoriness to treatment and poor outcome. Diabetes mellitus type 2 (T2D) and insulin resistance (IR) have been identified as risk factors for this more severe form of BD.

Objectives and aims

We investigated the rates of IR and T2D in patients with BD and whether this comorbidity is associated with specific clinical features of BD such as rapid cycling or treatment resistance.

Methods

IR and T2D were screened in patients with BD types I or II, who were on stable treatment with mood stabilizers. The response to treatment was assessed by means of the Alda scale.

Results

In a preliminary sample, we made a new diagnosis of IR in 40% of patients. The 1% of this sample had a diagnosis of T2D. The treatment response was worse in BD patients with comorbid IR or T2D as compared to those without metabolic abnormalities.

Conclusions

These findings show that IR and T2D have high prevalence in BD patients and have negative impact on treatment response.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
EV213
Information
European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S341
Copyright
Copyright © European Psychiatric Association 2016
Submit a response

Comments

No Comments have been published for this article.